Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Open Access
- 1 October 1994
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 94 (4) , 1383-1389
- https://doi.org/10.1172/jci117473
Abstract
Interferon-alpha induces durable cytogenetic remissions in about one-quarter of newly diagnosed patients with chronic myelogenous leukemia (CML). Even so, after short-term follow-up, previous studies have shown that residual leukemic cells can be detected by the polymerase chain reaction (PCR) in all of these individuals. The objectives of our study were therefore to obtain long-term follow-up data on residual disease in a cohort of complete responders and to determine if leukemic cells with clonogenic potential are present in patients despite the absence of relapse. We performed (a) serial analysis of blood and/or bone marrow for a reverse transcriptase PCR amplified BCR-ABL transcript at times well beyond the point that cytogenetic remission was first attained and (b) reverse transcriptase PCR of individually plucked myeloid and erythroid colonies for the presence of the same transcript. Seven CML patients who had previously attained complete cytogenetic remission while on interferon-alpha were investigated. Six of the seven patients were in complete cytogenetic remission at the time of analysis, whereas one patient had early evidence of cytogenetic relapse. With ongoing therapy, five patients with the longest follow-up eventually achieved PCR negativity at time periods of 27, 32, 36, 49, and 67 mo after a complete cytogenetic remission was first noted. Even so, residual disease was detected in progenitor cells derived from two patients, each of whom had been in continuous cytogenetic remission for approximately 2.5 and 3.5 yr, respectively. Progenitors expressing BCR-ABL transcripts were also detected in the patient with early cytogenetic relapse. These observations demonstrate that residual disease resides in colony-forming cells that should have the potential to repopulate the bone marrow. However, the presence of a minority of Ph-positive CML progenitor cells for a very long period of time is still compatible with durable remission, confirming that a situation of tumor dormancy may be induced in CML by interferon therapy.Keywords
This publication has 24 references indexed in Scilit:
- Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.Journal of Clinical Investigation, 1993
- Assay formats involving acridinium-ester-labeled DNA probes.Clinical Chemistry, 1989
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988
- Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.Proceedings of the National Academy of Sciences, 1988
- Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused geneCell, 1986
- Long-Term Marrow Culture Reveals Chromosomally Normal Hematopoietic Progenitor Cells in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1983
- Culture studies of human pluripotent hemopoietic progenitorsAnnals of Hematology, 1980
- RESULTS OF TREATMENT OF PH'+CHRONIC MYELOGENOUS LEUKEMIA WITH AN INTENSIVE TREATMENT REGIMEN (L-5 PROTOCOL)1979
- HEMATOLOGIC AND CYTOLOGIC CHARACTERIZATION OF 8-21 TRANSLOCATION ACUTE GRANULOCYTIC-LEUKEMIA1979
- GRANULO-ERYTHROPOIETIC COLONIES IN HUMAN BONE-MARROW, PERIPHERAL-BLOOD, AND CORD BLOOD1978